PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Orifarm UK Ltd
OU

Orifarm UK Ltd

Hemel Hempstead
SME

Orifarm UK Ltd is focused on improving access to affordable healthcare through parallel traded medicines, niche generics, prescription medicines, and consumer healthcare products. They work with wholesalers, pharmacies, and hospitals across Europe.

orifarm.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£1.4bn
Live
18
Buyers
2
12m
£1.3bn
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts18 / 24
  • Top buyers2
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Orifarm UK LtdUpdated 13 Jul 2026

At a glance · for buyers and watchdogs

Orifarm UK Ltd has won £1.4bn across 2 public-sector buyers, with 18 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
18 of 24Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 3
Parallel Traded MedicinesHelps create savings and improve access to treatments.
Niche Generics and Prescription MedicinesAddresses healthcare needs across therapeutic areas.
Consumer Healthcare ProductsSupports everyday health and wellbeing.

Extracted automatically from orifarm.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 18 live · 6 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
NHS England—01 Sept 2026£813.9m2 yrspending
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£403.7m2 yrspending
NHS National Framework for Golimumab Injection
NHS England—01 Nov 2025£60.0m12 mopending
NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
NHS England3360000001 Sept 2025£47.0m2 yrsLive
NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National
NHS England3360000001 Sept 2025£9.4m2 yrsLive
NHS Branded Medicines Tranche Framework for London and South of England
NHS England3360000001 Sept 2024£13.1m2 yrsLive
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
NHS England3360000001 Mar 2024£17.6m2.5 yrsLive
NHS South of England Branded Medicines - Tranche A - September 2023
NHS England3360000001 Sept 2023£7.6m2 yrsClosed
NHS London Branded Medicines - Tranche B - September 2023
NHS England3360000001 Sept 2023£6.4m2 yrsClosed
NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals
NHS England3360000001 May 2023£6.1m2 yrsClosed
Total live value £87.1m · mean award £57.7m1–10 of 24

Top buyers · 2 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
22 contracts
100%
since 2023
2
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
2 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire22 contracts
100%
Scotland2 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). Orifarm UK Ltd highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
OU
Orifarm UK Ltd
Yes£1.3bn—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 04 Mar 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
10015046
Status
Active
Type
Private limited
Incorporated
19 Feb 2016
Reg. office
Ground Floor, Suite A2 Breakspear Way, Breakspear Park, Hemel Hempstead, HP2 4TZ
SIC codes
82990
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • KRISTENSEN, Nicki Lund — director
    Appointed 30 Oct 2025
  • BRANDHOF, Thomas — director
    Appointed 25 Apr 2025
  • ERIKSEN, Mads Fink — director
    Appointed 25 Apr 2025
  • BØGH-SØRENSEN, Hans Carl — director
    Appointed 19 Feb 2016
  • Mr Hans Carl Bøgh-Sørensen — person with significant control
    voting rights 50 to 75 percent
  • Ms Anne-Charlotte Bøgh-Sørensen — person with significant control
    ownership of shares 25 to 50 percent
  • Mr Andreas Henrik Bøgh-Sørensen — person with significant control
    ownership of shares 25 to 50 percent
  • Mr Christian Ulrik Bøgh-Sørensen — person with significant control
    ownership of shares 25 to 50 percent

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
ORIFARM UK LTD
10015046 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.